49例输血型丙型肝炎患者病毒基因型鉴定及干扰素治疗效果观察  

HCV Genotype in 49 Patients of Posttransfusion Hepatitis C and Response to Interferon Therapy

作　　者：龚国忠[1] 郑宣鹤[1] 黄力[1] 赖力英[1] 

机构地区：[1]湖南医科大学附二院肝病研究中心,长沙410011

出　　处：《热带医学杂志》2001年第2期126-128,共3页Journal of Tropical Medicine

基　　金：国家自然科学基金部分资助 (批准号 :396 70 6 7)

摘　　要：目的　了解湖南地区输血后丙型肝炎病毒基因型分布情况 ,分析干扰素治疗效果的影响因素。方法采用混合引物PCR法检测 49例湖南地区输血后丙型肝炎基因型。根据ETR和SR 12生物应答和病毒应答率指标研究影响干扰素疗效的主要因素。结果　 49例病人可分型者 46例 ,全部为Ⅱ (1b)型 ,未发现其他基因型。 3例病人未能分型。对完成疗程的 2 6例基因Ⅱ型丙肝患者给予正规疗程干扰素治疗 ,结果显示感染时间是影响干扰素疗效的主要因素。感染时间在一年以内 ,ETR生化应答率和病毒应答率分别是 85 7% (12 / 14)和 78 6 % (11/ 14) ,SR 12生化应答率和病毒应答率为 6 4.3% (9/ 14)和 5 7.1% (8/ 14) ,这些指标均显著高于感染时间大于一年的病人(4 1 6 %、33 3%、16 7%和 8 33% )。结论　湖南地区输血后丙型肝炎HCV基因型主要为Ⅱ (1b)型。感染时间的长短是影响干扰素应答的主要因素 ,早期抗病毒治疗对基因Ⅱ型HCV感染仍能取得较满意疗效。Objective To explore the distribution of genotype of HCV in patients with post transfusion hepatitis C and the factors those affect the efficacy of interferon therapy.Method Multi-primer PCR established originally by Okamoto was used to genotype the HCV of the patients with post transfusion hepatitis C. ETR and SR-12 were applied to assess the efficay of interferon therapy. Result 46 cases of post transfusion hepatitis C were found to be infected by genotype Ⅱ(1b) HCV. 26 cases of genotype Ⅱ HCV infected patients were received the α-2b interferon therapy. The duration of HCV infection was an important factor that affected the result of interferon therapy. The patients with HCV infection less than 1 year had a significantly higher ETR and SR-12, both in biochemical response and virus response, than those with infection more than 1 year.Conclusion Genotype Ⅱ (1b) was the prevailing HCV genotype in patients with post transfusion hepatitis C. Duration of HCV infection could affect the efficantly of interferon therapy. Administration of antiviral agent within 1 year of the HCV infection might give a satisfactory outcome in the hepatitis C patients infected with HCV genotypy Ⅱ(1b)

关 键 词：输血后丙型肝炎 基因型 干扰素 

分 类 号：R512.63[医药卫生—内科学] R457.1[医药卫生—临床医学]